Clinical trial · Interventional
Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
A Multiple-center Phase II Study to Evaluate the Clinical Outcome of Reduced Conditioning Regimen With Melphalan, Busulfan and Fludarabine for Patients >=55 Years With Myeloid Malignancies.
NCT05436561CI-TRIAL-00105725recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Disease-free Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MBF-RIC | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MBF-RIC
- description
- Patients with MBF-RIC as conditioning regimen
- interventionNames
- Drug: MBF-RIC
Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- 2 year
- description
- survival without disease relapse or progression
Secondary outcomes (4)
- measure
- overall survival
- timeFrame
- 2 year
- description
- survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 55 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age 55-65 * patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or haplo-identical donors. * patients with AML in remission, or MDS in any stage, or CMML in any stage * inform consent provided Exclusion Criteria: * patients with abnormal liver (\>3N), renal (1.5N) or cardiac function * patients with active infection
References
Publications (0)
Data not yet available
No reference posted for this study.